Can eribulin slow advanced cervical cancer? new trial results are in.
NCT ID NCT01676818
First seen Nov 06, 2025 · Last updated Jun 18, 2026 · Updated 24 times
Summary
This study tested a chemotherapy drug called eribulin in 32 people with advanced or recurrent cervical cancer that had spread or come back. The goal was to see how long the drug could keep the cancer from growing and to check for side effects. Participants had already received up to one prior chemotherapy treatment. The results help doctors understand if eribulin is a useful option for controlling this type of cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT CERVICAL CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
USC Norris Comprehensive Cancer Center
Los Angeles, California, 90033, United States
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.